Jazz Pharmaceuticals plc stock: filings, catalysts and timeline
Sign in to follow
FundamentalsWhat is this?HideToo few of the required measures on file
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HideToo few of the required measures on file
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideBalanced
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its Evidence strength.
Discovery Gap: Medium (20/100) · Gap confidence 54/100
Some evidence isn't yet fully priced in.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
Gap confidenceWhat is this?HideModerate 54/100How fully AIR could measure this Gap.
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Evidence strengthWhat is this?HideModerate 42/100Support behind the full AIR read, not only the Gap.
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
This month at a glance
Capital returns
Latest buyback
Buyback approved · Approved a $500 million share buyback.
Filed 2 Nov 2026 · As stated in the filing →
Evidence timeline
- Expected
Wed 24 Feb · expected 10-K
Last year filed 24 Feb 2026.
Wed 5 May · expected 10-Q
Last year filed 5 May 2026.
- Filed
Mon 2 Nov · 8-K
8-K · Item 2.02 — Results of operations
Jazz Pharmaceuticals reported Q3 2026 revenues of $1.2B (+10% YoY), raised full-year guidance to $4.775–$4.85B, achieved FDA approval and rapid Ziihera launch in HER2+ GEA, and closed Actio acquisition adding ABS-1230 to rare epilepsy portfolio.
Gap Medium · 13 → Medium · 20Progress is running ahead of attention.
The price trend strengthened.
- Buyback approvedApproved a $500 million share buyback. As stated in the filing →
Mon 2 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
Gap Medium · 13 → Medium · 20Progress is running ahead of attention.
The price trend strengthened.
Mon 26 Oct · 8-K
8-K · Item 2.02 — Results of operations
Jazz Pharmaceuticals reports ~$755M pre-tax IPR&D charge from Actio Biosciences acquisition (closed Sept 15, 2026), reducing Q3 2026 GAAP and non-GAAP EPS by ~$11.00 per share. Charge is non-tax-deductible.
Recognition: Strong 74 → Strong 71Gap Medium · 20 → Medium · 14Market attention has faded.
The gap narrowed as the filings read less positively.
The price trend weakened.
Fri 9 Oct · 8-K
8-K · Item 5.02 — Director or officer change
Recognition: Strong 76 → Strong 73Market attention has faded.
The price trend weakened.
Wed 23 Sep · 8-K
8-K · Items 1.01, 2.03 — Material agreement
Jazz Pharmaceuticals refinanced its term loan facility, extending maturity from May 2028 to May 2033 and reducing interest margin by 50 basis points. Principal amount remains $1.895 billion.
Tue 15 Sep · 8-K
Mon 31 Aug · 8-K
Tue 25 Aug · 8-K
Mon 10 Aug · 8-K
Mon 10 Aug · 8-K
Mon 3 Aug · 8-K
Mon 3 Aug · 10-Q
Quarterly report (10-Q), period ending 27 Jul 2026
Fri 24 Jul · 8-K
Fri 29 May · 8-K
Tue 5 May · 10-Q
Quarterly report (10-Q), period ending 28 Apr 2026
Tue 5 May · 8-K
Tue 24 Feb · 10-K
Annual report (10-K), FY2026
Tue 24 Feb · 8-K
Mon 12 Jan · 8-K
Mon 17 Nov · 8-K
Wed 5 Nov · 10-Q
Quarterly report (10-Q), period ending 29 Oct 2025
Wed 5 Nov · 8-K
Tue 28 Oct · 8-K
Wed 22 Oct · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.